ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Sold by Blackstone Inc.

Blackstone Inc. lowered its position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 38.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 936,607 shares of the company's stock after selling 585,827 shares during the quarter. Blackstone Inc. owned about 1.48% of ABIVAX Société Anonyme worth $6,856,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at approximately $29,000. R Squared Ltd bought a new stake in ABIVAX Société Anonyme during the fourth quarter valued at $36,000. Bank of America Corp DE raised its holdings in shares of ABIVAX Société Anonyme by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after purchasing an additional 1,990 shares during the period. Ameriprise Financial Inc. bought a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth about $85,000. Finally, Guggenheim Capital LLC acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $92,000. Institutional investors own 47.91% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ABIVAX Société Anonyme has an average rating of "Buy" and a consensus target price of $34.00.

ABIVAX Société Anonyme Price Performance

NASDAQ:ABVX opened at $7.12 on Tuesday. ABIVAX Société Anonyme has a 1 year low of $4.77 and a 1 year high of $15.06. The business has a fifty day moving average of $6.59 and a 200-day moving average of $7.48.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.